Leonteq AG
SIX:LEON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Leonteq AG
SIX:LEON
|
CH |
|
Elevation Oncology Inc
NASDAQ:ELEV
|
US |
|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
KR |
|
P
|
Prodigy PCL
SET:PDG
|
TH |
|
Kudelski SA
F:KUD
|
CH |
|
US Nuclear Corp
OTC:UCLE
|
US |
|
AFC Energy PLC
LSE:AFC
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LEON's stock price target?
Not Available
LEON doesn't have any price targets made by Wall Street professionals.
What is Leonteq AG's Revenue forecast?
Projected CAGR
14%
For the last 14 years the
compound annual growth rate for
Leonteq AG's revenue is
3%.
The projected
CAGR
for the next 3 years is
14%.